OCEA Stock Overview
A biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Ocean Biomedical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.58 |
| 52 Week High | US$12.08 |
| 52 Week Low | US$0.52 |
| Beta | -0.32 |
| 11 Month Change | 4.97% |
| 3 Month Change | -46.20% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.75% |
Recent News & Updates
Shareholder Returns
| OCEA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.6% | 2.5% | 2.2% |
| 1Y | n/a | 16.1% | 31.6% |
Return vs Industry: Insufficient data to determine how OCEA performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how OCEA performed against the US Market.
Price Volatility
| OCEA volatility | |
|---|---|
| OCEA Average Weekly Movement | 15.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OCEA's share price has been volatile over the past 3 months.
Volatility Over Time: OCEA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 9 | Elizabeth Ng | www.oceanbiomedical.com |
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP.
Ocean Biomedical, Inc. Fundamentals Summary
| OCEA fundamental statistics | |
|---|---|
| Market cap | US$20.46m |
| Earnings (TTM) | -US$85.08m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs OCEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCEA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$85.08m |
| Earnings | -US$85.08m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -155.9% |
How did OCEA perform over the long term?
See historical performance and comparison